Stockholders' Equity (Tables)

9 Months Ended

Apr. 30, 2017

Stockholders' Equity Note [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended April 30,				Nine months ended April 30,
	2017		2016		2017		2016
Stock options	$	204	$	143	$	586	$	351
Restricted stock		5		6		15		19
	$	209	$	149	$	601	$	370

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended April 30,				Nine months ended  April 30,
	2017		2016		2017		2016
Cost of clinical laboratory services	$	2	$	2	$	5	$	5
Selling, general and administrative		207		147		596		365
	$	209	$	149	$	601	$	370

Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option activity during the nine month period ended April 30, 2017:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2016		1,808,875		$	3.43
Awarded		493,996		$	7.07
Exercised		(45,358	)	$	3.28		$	338
Cancelled or expired		(9,000	)	$	4.74
Outstanding at end of period		2,248,513		$	4.23	2.7 years	$	10,433
Exercisable at end of period		1,484,993		$	3.26	1.2 years	$	8,231

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2017 is as follows:

	Awards			Weighted Average Award Price
Outstanding at July 31, 2016		8,501		$	4.13
Awarded		—			—
Vested		(2,813	)	$	(3.49	)
Forfeited		—			—
Unvested at end of period		5,688		$	1.96